Literature DB >> 30629811

Clarithromycin for the treatment of adult chronic rhinosinusitis: a systematic review and meta-analysis.

Zhenxiao Huang1, Bing Zhou1.   

Abstract

BACKGROUND: The aim of this systematic review (SR) was to assess the safety and efficacy of oral clarithromycin for the treatment of chronic rhinosinusitis (CRS).
METHODS: This SR and meta-analysis was conducted based on the recommendations outlined in the Cochrane Handbook for SR of Interventions. The protocol was registered on PROSPERO, an international prospective register of SRs. English and Chinese electronic databases were searched, and only randomized controlled trials were included.
RESULTS: Seventeen studies with 1738 patients were included. Eleven studies evaluated whether adding oral clarithromycin to intranasal steroid spray with or without nasal saline irrigation was more effective than intranasal steroid spray alone. This combined treatment regimens statistically significantly improve clinical symptoms in the medium term (1 to 3 months), the endoscopic and computed tomography (CT) scores in both the short term (<1 month) and medium term, and clinical symptoms and the endoscopic score in the long term (>3 months). The incidence of adverse events did not increase with the use of this combination therapy. No significant difference was identified between treatment with oral clarithromycin and intranasal steroid spray alone groups in term of symptoms, endoscopic score, and CT score.
CONCLUSION: For the treatment of CRS, adding oral clarithromycin to intranasal steroid spray with or without nasal saline irrigation may achieve better results than using intranasal steroid spray with or without nasal saline irrigation. There is insufficient evidence to confirm that oral clarithromycin alone may have similar efficacy as nasal glucocorticoid spray alone. High-quality evidence in this area is needed.
© 2019 ARS-AAOA, LLC.

Entities:  

Keywords:  chronic rhinosinusitis; clarithromycin; macrolide; meta-analysis; systematic review

Mesh:

Substances:

Year:  2019        PMID: 30629811     DOI: 10.1002/alr.22281

Source DB:  PubMed          Journal:  Int Forum Allergy Rhinol        ISSN: 2042-6976            Impact factor:   3.858


  2 in total

Review 1.  Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches.

Authors:  Atsushi Kato; Anju T Peters; Whitney W Stevens; Robert P Schleimer; Bruce K Tan; Robert C Kern
Journal:  Allergy       Date:  2021-09-15       Impact factor: 14.710

2.  Erythromycin reduces nasal inflammation by inhibiting immunoglobulin production, attenuating mucus secretion, and modulating cytokine expression.

Authors:  Ting-Ting Yen; Rong-San Jiang; Ching-Yun Chang; Chih-Ying Wu; Kai-Li Liang
Journal:  Sci Rep       Date:  2021-11-05       Impact factor: 4.379

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.